PATENT CLAIM ANALYSIS

Application Number: 15958440
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "304000"]

Abstract:
Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogenesis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogenesis and treating myopia by administering an effective amount of one or more anti-chondrogenesis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Claim (Index 6):
The pharmaceutical composition of  claim 1 , wherein the NSAID is about 0.01% to about 0.2% by weight diclofenac.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.47368
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15747153', '11528902', '13453765', '15159357', '14674786']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7398513808171074
- 35 USC 102 Novelty (BERT): 0.5005150993121358
- Combined Prediction Score: 0.7159177526666103
- Mean Citation Score: 137.95728400000002
- Max Citation Score: 140.53404
- Similarity Product: 78.98045387919903

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test